Contact

eClinicalOS™ Mobile App Breaks New Ground for Clinical Researchers eClinical, Study Connect, eCOS, Study Connect™ App Enables the Mobile Management of Randomization, Inventory Management and Unblinding in Clinical Trials

eClinicalOS™ Mobile App Breaks New Ground for Clinical Researchers

Study Connect™ App Enables the Mobile Management of Randomization, Inventory Management and Unblinding in Clinical Trials

Morrisville, N.C. (June 3, 2015) – Study Connect™, a new mobile app from Merge eClinical, allows eClinicalOS (eCOS) users to perform a wide array of clinical trial management functions from their iOS-based mobile devices.

Seamlessly integrated with eCOS, Study Connect™ enables researchers to:

  • Manage randomization of subjects 
  • Coordinate dispensing and inventory management
  • Unblind individual subjects, as circumstances warrant
  • Stay connected with real-time customized notifications
  • Monitor enrollment and establish milestone alerts
  • Share top-level statistics for each study with key stakeholders using the study dashboard
  • Expedite approval response times for critical study decisions such as patient study eligibility
  • Maintain security with the ability to set customized role-based permissions for individual studies.

“We’re pushing the boundaries of what’s possible in a mobile environment for clinical researchers,” said Zaher El-Assi, president of Merge eClinical. “More and more, researchers need to be able to perform virtually any study task from their tablets and smartphones. Managing study decisions and being notified of adverse events alone would make for a useful mobile EDC, but Study Connect gives eCOS users so much more. It really serves as a natural extension of their desktops and laptops.”
 
According to Mr. El-Assi, while there are a handful of mobile clinical research apps on the market, nearly all are limited solely to patient-reporting functions.
 
“With more studies being conducted at multiple sites across multiple time zones around the world, it’s critical that researchers not just be able to monitor crucial study variables, but also to respond to them in real time,” he said. “There are few, if any, other industries where the consequences of the old ‘time-is-money’ adage are felt more acutely than in drug development. By giving eCOS users more power to do more tasks while on the go, we’re helping them make the most of every minute.”
 
Mr. El-Assi noted that in many less-developed countries cellular network are often more reliable than electricity, meaning that vital study functions need not cease when power grids fail.
 
Study Connect is available in the App Store and can be reached through this link. Designed to work on both the iPad™ and iPhone™, Study Connect can be integrated into existing trials through the Clinical Configurator, the company’s exclusive online tool for the planning and budgeting of studies on the eCOS platform.
 
“While Merge eClinical is exceptionally proud to be among the first EDC providers to offer true mobile study management capabilities, we’ve only scratched the surface of what’s possible,” said Mr. El-Assi. “Our R&D team is already working on the next update to Study Connect, and we’re excited to see what ideas eCOS users send to us on how they think we can make it an even more useful app for them.”

About Merge eClinical
Merge eClinical is a division of Merge Healthcare, Inc. (NASDAQ: MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare. eClinicalOS (eCOS) the company’s flagship product, is a single, scalable, cloud-based platform researchers can configure to suit a study’s precise needs. From monitoring inventory and managing randomization to endpoint adjudication and archiving results, users pay only for the options they use. Studies built within eCOS can launch in as few as 10 days, and the average deployment time from project start is 40 days. Through active sites in 80-plus countries, more than 50,000 clinical research professionals in small and large organizations have entrusted their study management needs to eCOS. More information is available at www.eclinicalos.com, and you can follow us at @goecos.

About Merge
Merge is a leading provider of innovative enterprise imaging, interoperability and clinical systems that seek to advance healthcare. Merge’s enterprise and cloud-based technologies for image intensive specialties provide access to any image, anywhere, any time. Merge also provides clinical trials software with end-to-end study support in a single platform and other intelligent health data and analytics solutions. With solutions that have been used by providers for more than 25 years, Merge is helping to reduce costs, improve efficiencies and enhance the quality of healthcare worldwide. For more information, visit merge.com and follow us @MergeHealthcare.

Contact:
Aaron Mazze
Merge eClinical
919.653-3467
Aaron.Mazze@merge.com

 Download this press release >>

© 2017 IBM Watson Health. All Rights Reserved. Privacy | Terms | Email Signup | Sitemap